Matthew Sale
Matthew Sale
Verified email at ucsf.edu
Title
Cited by
Cited by
Year
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
CJ Caunt, MJ Sale, PD Smith, SJ Cook
Nature Reviews Cancer 15 (10), 577-592, 2015
2772015
Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells
AS Little, K Balmanno, MJ Sale, S Newman, JR Dry, M Hampson, ...
Sci. Signal. 4 (166), ra17-ra17, 2011
1842011
Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation
CL Cope, R Gilley, K Balmanno, MJ Sale, KD Howarth, M Hampson, ...
Journal of cell science 127 (4), 788-800, 2014
752014
The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance
MJ Sale, SJ Cook
Biochemical Journal 450 (2), 285-294, 2013
522013
Control of cell death and mitochondrial fission by ERK 1/2 MAP kinase signalling
SJ Cook, K Stuart, R Gilley, MJ Sale
The FEBS journal 284 (24), 4177-4195, 2017
452017
Lysine acetylation controls local protein conformation by influencing proline isomerization
FS Howe, I Boubriak, MJ Sale, A Nair, D Clynes, A Grijzenhout, ...
Molecular cell 55 (5), 733-744, 2014
282014
Intrinsic and acquired resistance to MEK1/2 inhibitors in cancer
MJ Sale, SJ Cook
Biochemical Society Transactions 42 (4), 776-783, 2014
232014
That which does not kill me makes me stronger; combining ERK 1/2 pathway inhibitors and BH 3 mimetics to kill tumour cells and prevent acquired resistance
MJ Sale, SJ Cook
British journal of pharmacology 169 (8), 1708-1722, 2013
202013
Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling
AS Little, K Balmanno, MJ Sale, PD Smith, SJ Cook
Biochemical Society Transactions 40 (1), 73-78, 2012
182012
MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAF V600E amplification whereas KRAS G13D amplification promotes EMT-chemoresistance
MJ Sale, K Balmanno, J Saxena, E Ozono, K Wojdyla, RE McIntyre, ...
Nature communications 10 (1), 1-22, 2019
92019
A correction to the research article titled:" Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells …
AS Little, K Balmanno, MJ Sale, S Newman, JR Dry, M Hampson, ...
Science signaling 4 (170), er2-er2, 2011
82011
Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors
MJ Sale, E Minihane, NR Monks, R Gilley, FM Richards, KP Schifferli, ...
Nature communications 10 (1), 1-19, 2019
32019
The increase in BIK expression following ERK1/2 pathway inhibition is a consequence of G1 cell-cycle arrest and not a direct effect on BIK protein stability
MJ Sale, SJ Cook
Biochemical Journal 459 (3), 513-524, 2014
32014
Resistance to ERK1/2 pathway inhibitors; sweet spots, fitness deficits and drug addiction
MJ Sale, K Balmanno, SJ Cook
2019
The system can't perform the operation now. Try again later.
Articles 1–14